EDESA BIOTECH, INC. APIC, Share-based Payment Arrangement, Recognition and Exercise
EDESA BIOTECH, INC. (EDSA) reported APIC, Share-based Payment Arrangement, Recognition and Exercise of $333.68 thousand for the 3-month period ending 2022-12-31, per its 10-Q filed 2023-02-10.
Discontinued › Notes › Equity › Stockholders' Equity Note
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions · last filed 2023-02-10
- EDESA BIOTECH, INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2022-12-31 was $333.68K, a 45.23% decline year-over-year.
- EDESA BIOTECH, INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2022-06-30 was $565.38K, a 48.62% decline year-over-year.
- EDESA BIOTECH, INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2022-03-31 was $630.01K, a 34.78% increase year-over-year.
- EDESA BIOTECH, INC. apic, share-based payment arrangement, recognition and exercise for the quarter ending 2021-12-31 was $609.28K.
- EDESA BIOTECH, INC. apic, share-based payment arrangement, recognition and exercise for fiscal 2021 was $3.20M, a 434.04% increase from fiscal 2020.
- EDESA BIOTECH, INC. apic, share-based payment arrangement, recognition and exercise for fiscal 2020 was $598.36K.
- EDESA BIOTECH, INC. apic, share-based payment arrangement, recognition and exercise for fiscal 2018 was $81.34K.
| Period end | APIC, Share-based Payment Arrangement, Recognition and Exercise 3 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 3 month as first filed | APIC, Share-based Payment Arrangement, Recognition and Exercise 6 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 9 month | APIC, Share-based Payment Arrangement, Recognition and Exercise 12 month |
|---|---|---|---|---|---|
| 2022-12-31 | $333.68K 10-Q · filed 2023-02-10 | ||||
| 2022-06-30 | $565.38K 10-Q · filed 2022-08-12 | $1.20M derived: sum of 2 quarters · filed 2022-08-12 | $1.80M 10-Q · filed 2022-08-12 | $2.71M derived: sum of 4 quarters · filed 2023-02-10 | |
| 2022-03-31 | $630.01K 10-Q · filed 2022-05-13 | $1.24M 10-Q · filed 2022-05-13 | $2.14M derived: sum of 3 quarters · filed 2023-02-10 | $3.24M derived: sum of 4 quarters · filed 2023-02-10 | |
| 2021-12-31 | $609.28K 10-Q · filed 2023-02-10 | $1.51M derived: sum of 2 quarters · filed 2023-02-10 | $2.61M derived: sum of 3 quarters · filed 2023-02-10 | $3.08M derived: sum of 4 quarters · filed 2023-02-10 | |
| 2021-09-30 | $904.67K derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-28 | $2.01M derived: sum of 2 quarters · filed 2022-08-12 | $2.47M derived: sum of 3 quarters · filed 2022-08-12 | $3.20M 10-K · filed 2021-12-28 | |
| 2021-06-30 | $1.10M 10-Q · filed 2022-08-12 | $1.57M derived: sum of 2 quarters · filed 2022-08-12 | $2.29M 10-Q · filed 2022-08-12 | $1.65M derived: sum of 4 quarters · filed 2022-08-12 | |
| 2021-03-31 | $467.44K 10-Q · filed 2022-05-13 | $1.19M 10-Q · filed 2022-05-13 | $553.83K derived: sum of 3 quarters · filed 2022-05-13 | $677.02K derived: sum of 4 quarters · filed 2022-05-13 | |
| 2020-12-31 | $0.00 10-Q · filed 2022-02-14 | $722.91K 10-Q · filed 2021-02-16 | $86.39K derived: sum of 2 quarters · filed 2022-02-14 | $209.58K derived: sum of 3 quarters · filed 2022-02-14 | $589.58K derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-09-30 | $86.39K derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-28 | $209.58K derived: sum of 2 quarters · filed 2021-12-28 | $589.58K derived: sum of 3 quarters · filed 2021-12-28 | $598.36K 10-K · filed 2021-12-28 | |
| 2020-06-30 | $123.19K 10-Q · filed 2021-08-13 | $503.19K derived: sum of 2 quarters · filed 2021-08-13 | $511.97K 10-Q · filed 2021-08-13 | $522.17K derived: sum of 4 quarters · filed 2021-08-13 | |
| 2020-03-31 | $380.00K 10-Q · filed 2020-05-15 | $388.77K 10-Q · filed 2021-05-14 | $398.98K derived: sum of 3 quarters · filed 2021-02-16 | $410.40K derived: sum of 4 quarters · filed 2021-02-16 | |
| 2019-12-31 | $8.78K 10-Q · filed 2021-02-16 | $18.98K derived: sum of 2 quarters · filed 2021-02-16 | $30.40K derived: sum of 3 quarters · filed 2021-02-16 | $43.85K derived: sum of 4 quarters · filed 2021-02-16 | |
| 2019-09-30 | $10.21K derived: 10-K 9 month − 10-Q 6 month · filed 2020-12-07 | $21.63K derived: sum of 2 quarters · filed 2020-12-07 | $35.07K 10-K · filed 2020-12-07 | $46.51K derived: sum of 4 quarters · filed 2020-12-07 | |
| 2019-06-30 | $11.42K 10-Q · filed 2020-08-12 | $24.87K 10-Q · filed 2019-08-14 | $36.30K 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $13.45K 10-Q · filed 2020-05-15 | $24.88K 10-Q · filed 2020-05-15 | |||
| 2018-12-31 | $11.43K 10-Q · filed 2020-02-13 | $81.34K 10-KT · filed 2019-12-12 | |||
| 2018-06-30 | $23.47K 10-Q · filed 2019-08-14 | $46.68K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |